Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry.
Antidepressant medication
Depression symptoms
Major depressive disorder
Meta-analysis
Precision psychiatry
Psychotherapy
Symptom-oriented therapy metric
Systematic review
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
05 06 2020
05 06 2020
Historique:
received:
12
04
2018
accepted:
07
05
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Antidepressant medication (ADM) and psychotherapy are effective treatments for major depressive disorder (MDD). It is unclear, however, if treatments differ in their effectiveness at the symptom level and whether symptom information can be utilised to inform treatment allocation. The present study synthesises comparative effectiveness information from randomised controlled trials (RCTs) of ADM versus psychotherapy for MDD at the symptom level and develops and tests the Symptom-Oriented Therapy (SOrT) metric for precision treatment allocation. First, we conducted systematic review and meta-analyses of RCTs comparing ADM and psychotherapy at the individual symptom level. We searched PubMed Medline, PsycINFO, and the Cochrane Central Register of Controlled Trials databases, a database specific for psychotherapy RCTs, and looked for unpublished RCTs. Random-effects meta-analyses were applied on sum-scores and for individual symptoms for the Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) measures. Second, we computed the SOrT metric, which combines meta-analytic effect sizes with patients' symptom profiles. The SOrT metric was evaluated using data from the Munich Antidepressant Response Signature (MARS) study (n = 407) and the Emory Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study (n = 234). The systematic review identified 38 RCTs for qualitative inclusion, 27 and 19 for quantitative inclusion at the sum-score level, and 9 and 4 for quantitative inclusion on individual symptom level for the HAM-D and BDI, respectively. Neither meta-analytic strategy revealed significant differences in the effectiveness of ADM and psychotherapy across the two depression measures. The SOrT metric did not show meaningful associations with other clinical variables in the MARS sample, and there was no indication of utility of the metric for better treatment allocation from PReDICT data. This registered report showed no differences of ADM and psychotherapy for the treatment of MDD at sum-score and symptom levels. Symptom-based metrics such as the proposed SOrT metric do not inform allocation to these treatments, but predictive value of symptom information requires further testing for other treatment comparisons.
Sections du résumé
BACKGROUND
Antidepressant medication (ADM) and psychotherapy are effective treatments for major depressive disorder (MDD). It is unclear, however, if treatments differ in their effectiveness at the symptom level and whether symptom information can be utilised to inform treatment allocation. The present study synthesises comparative effectiveness information from randomised controlled trials (RCTs) of ADM versus psychotherapy for MDD at the symptom level and develops and tests the Symptom-Oriented Therapy (SOrT) metric for precision treatment allocation.
METHODS
First, we conducted systematic review and meta-analyses of RCTs comparing ADM and psychotherapy at the individual symptom level. We searched PubMed Medline, PsycINFO, and the Cochrane Central Register of Controlled Trials databases, a database specific for psychotherapy RCTs, and looked for unpublished RCTs. Random-effects meta-analyses were applied on sum-scores and for individual symptoms for the Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) measures. Second, we computed the SOrT metric, which combines meta-analytic effect sizes with patients' symptom profiles. The SOrT metric was evaluated using data from the Munich Antidepressant Response Signature (MARS) study (n = 407) and the Emory Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study (n = 234).
RESULTS
The systematic review identified 38 RCTs for qualitative inclusion, 27 and 19 for quantitative inclusion at the sum-score level, and 9 and 4 for quantitative inclusion on individual symptom level for the HAM-D and BDI, respectively. Neither meta-analytic strategy revealed significant differences in the effectiveness of ADM and psychotherapy across the two depression measures. The SOrT metric did not show meaningful associations with other clinical variables in the MARS sample, and there was no indication of utility of the metric for better treatment allocation from PReDICT data.
CONCLUSIONS
This registered report showed no differences of ADM and psychotherapy for the treatment of MDD at sum-score and symptom levels. Symptom-based metrics such as the proposed SOrT metric do not inform allocation to these treatments, but predictive value of symptom information requires further testing for other treatment comparisons.
Identifiants
pubmed: 32498707
doi: 10.1186/s12916-020-01623-9
pii: 10.1186/s12916-020-01623-9
pmc: PMC7273646
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
170Subventions
Organisme : Bundesministerium für Bildung und Forschung (DE)
ID : 01ES0811
Pays : International
Organisme : Bundesministerium für Bildung und Forschung
ID : 01EE1401D
Pays : International
Organisme : NIMH NIH HHS
ID : P50 MH077083
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH080880
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025008
Pays : United States
Organisme : Foundation for the National Institutes of Health
ID : M01 RR0039
Pays : International
Références
Am J Psychiatry. 2007 May;164(5):778-88
pubmed: 17475737
J Clin Psychol. 2008 Jun;64(6):728-46
pubmed: 18473339
Psychol Assess. 2016 Nov;28(11):1354-1367
pubmed: 26821198
Annu Rev Psychol. 2014;65:267-300
pubmed: 24405361
Arch Gen Psychiatry. 1979 Dec;36(13):1450-6
pubmed: 518245
Psychother Res. 2018 May;28(3):347-355
pubmed: 29224503
Biol Psychiatry. 2016 Sep 15;80(6):424-431
pubmed: 26707087
Acta Psychiatr Scand. 2013 Oct;128(4):271-81
pubmed: 23240706
Brain Behav Immun. 2019 Feb;76:74-81
pubmed: 30414442
Trials. 2012 Jul 09;13:106
pubmed: 22776534
Stat Med. 2000 Nov 30;19(22):3127-31
pubmed: 11113947
JAMA Psychiatry. 2013 Aug;70(8):821-9
pubmed: 23760393
BMJ. 1992 Apr 4;304(6831):883-7
pubmed: 1392754
J Consult Clin Psychol. 1979 Oct;47(5):818-36
pubmed: 389965
Psychol Med. 2020 Dec;50(16):2682-2690
pubmed: 31615595
PLoS One. 2014 Feb 28;9(2):e90311
pubmed: 24587318
JAMA Psychiatry. 2014 Jun;71(6):706-15
pubmed: 24789675
BMJ. 1995 Feb 18;310(6977):441-5
pubmed: 7873952
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Psychother Res. 2020 Feb;30(2):137-150
pubmed: 30632922
Mol Psychiatry. 2016 Apr;21(4):523-30
pubmed: 25917369
Arch Gen Psychiatry. 2005 Apr;62(4):409-16
pubmed: 15809408
Neuropharmacology. 2014 Nov;86:125-32
pubmed: 25036609
Nat Rev Dis Primers. 2016 Sep 15;2:16065
pubmed: 27629598
Gigascience. 2019 Jul 1;8(7):
pubmed: 31307061
Psychol Med. 2019 Aug;49(11):1869-1878
pubmed: 30207254
Br J Psychiatry. 1981 Sep;139:181-9
pubmed: 7317698
J Clin Psychopharmacol. 2011 Apr;31(2):180-6
pubmed: 21346613
Arch Gen Psychiatry. 1992 Oct;49(10):774-81
pubmed: 1417429
J Consult Psychol. 1967 Apr;31(2):109-18
pubmed: 5342732
Behav Ther. 2017 Jul;48(4):490-500
pubmed: 28577585
World Psychiatry. 2020 Feb;19(1):92-107
pubmed: 31922679
BMC Psychiatry. 2008 May 16;8:36
pubmed: 18485191
Psychol Rep. 1995 Oct;77(2):403-20
pubmed: 8559866
J Affect Disord. 2008 Jul;109(1-2):183-8
pubmed: 18061276
Am J Geriatr Psychiatry. 2001 Summer;9(3):225-40
pubmed: 11481130
Am J Psychiatry. 2017 Jun 1;174(6):533-545
pubmed: 28335622
World Psychiatry. 2013 Jun;12(2):137-48
pubmed: 23737423
Lancet. 2018 Apr 7;391(10128):1357-1366
pubmed: 29477251
PLoS One. 2014 Jan 08;9(1):e83875
pubmed: 24416178
Br J Psychiatry. 2000 Oct;177:312-8
pubmed: 11116771
Behav Cogn Psychother. 2014 Nov;42(6):693-705
pubmed: 23867053
Psychother Res. 2015;25(5):612-24
pubmed: 25041333
J Affect Disord. 2014 Jan;152-154:262-7
pubmed: 24140226
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
BMC Med. 2011 Jul 26;9:90
pubmed: 21791035
Psychol Med. 2011 Jan;41(1):151-62
pubmed: 20380782
World Psychiatry. 2019 Jun;18(2):183-191
pubmed: 31059603
PLoS One. 2015 Nov 10;10(11):e0140771
pubmed: 26554707
Mol Psychiatry. 2016 Oct;21(10):1366-71
pubmed: 26728563
Arch Gen Psychiatry. 1999 May;56(5):431-7
pubmed: 10232298
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Br J Psychiatry. 2013 Mar;202(3):204-11
pubmed: 23391727
Psychother Psychosom. 2007;76(5):289-97
pubmed: 17700049
BMJ Open. 2017 Feb 13;7(2):e013478
pubmed: 28193851
J Clin Psychiatry. 2016 Dec;77(12):e1584-e1590
pubmed: 28086005
Arch Gen Psychiatry. 2001 Jul;58(7):641-8
pubmed: 11448369
J Psychiatr Res. 2009 Jan;43(3):215-29
pubmed: 18586274
Psychol Med. 2018 May;48(7):1102-1110
pubmed: 28889804
World Psychiatry. 2016 Oct;15(3):245-258
pubmed: 27717254
J Consult Clin Psychol. 2006 Aug;74(4):658-70
pubmed: 16881773
Am J Psychiatry. 2017 Jun 1;174(6):546-556
pubmed: 28335624
Behav Res Ther. 2013 Jul;51(7):392-8
pubmed: 23644038
Am J Psychiatry. 2012 Jan;169(1):22-30
pubmed: 22193528
Psychother Psychosom. 2008;77(6):351-7
pubmed: 18701831
Biol Psychiatry. 2008 Jun 15;63(12):1103-10
pubmed: 18191112
J Clin Epidemiol. 2016 Jun;74:119-23
pubmed: 26780258
Stat Med. 2013 May 20;32(11):1964-73
pubmed: 23303653
J Affect Disord. 2015 Feb 1;172:96-102
pubmed: 25451401
Psychiatry Res. 2017 Jul;253:174-181
pubmed: 28388454
Psychiatr Serv. 2009 Nov;60(11):1439-45
pubmed: 19880458
JAMA Psychiatry. 2016 Jan;73(1):87-8
pubmed: 26579988
Behav Res Ther. 2020 Feb;125:103507
pubmed: 31896529
J Consult Clin Psychol. 2012 Jun;80(3):342-53
pubmed: 22428942
BMJ. 2000 Jan 1;320(7226):26-30
pubmed: 10617523
J Affect Disord. 2017 Jan 15;208:191-197
pubmed: 27792962
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Psychol Med. 2016 Sep;46(12):2455-65
pubmed: 27406289
Arch Gen Psychiatry. 1989 Nov;46(11):971-82; discussion 983
pubmed: 2684085
BMC Med. 2015 Apr 06;13:72
pubmed: 25879936
PLoS Med. 2013;10(5):e1001454
pubmed: 23723742
Biol Psychiatry. 2015 Feb 1;77(3):285-294
pubmed: 25109665
Br J Psychiatry. 2014 Feb;204(2):144-50
pubmed: 24311553
Biometrics. 1990 Dec;46(4):1171-8
pubmed: 2085632
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
JAMA. 2003 Jul 2;290(1):57-65
pubmed: 12837712
Mol Psychiatry. 2018 Feb;23(2):335-343
pubmed: 27752078
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):721-730
pubmed: 28645191
JAMA Psychiatry. 2014 Dec 1;71(12):1381-91
pubmed: 25322082
Br J Psychiatry. 1997 Oct;171:328-34
pubmed: 9373420
J Clin Psychiatry. 2012 Jan;73(1):66-73
pubmed: 22152401
Psychol Med. 2019 May;49(7):1118-1127
pubmed: 29962359
N Engl J Med. 2000 May 18;342(20):1462-70
pubmed: 10816183